Anna Ochsner

Anna Ochsner

Auto-generated profile, based on publicly available information

Anna Ochsner

Laboratory of Translational Oncology and Translational Cancer Therapeutics, Warren Alpert Medical School of Brown University, Providence, RI

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 December 2023 in Cancer Epidemiology
Verified
Journal Article
Closed access
BGBorivoj Golijanin
Borivoj Golijanin
VBVikas Bhatt
Vikas Bhatt
AHAlexander Homer
Alexander Homer
KMKamil Malshy
Kamil Malshy
AOAnna Ochsner
Anna Ochsner
EHElias Hyams
Elias Hyams

28 December 2024 in Clinical Genitourinary Cancer
Verified
Journal Article
Closed access
AOAnna Ochsner
Anna Ochsner
KMKamil Malshy
Kamil Malshy
BGBorivoj Golijanin
Borivoj Golijanin
AMAnthony Mega
Anthony Mega
SCScott Collins
Scott Collins
DGDragan Golijanin
Dragan Golijanin

24 September 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
MGMaryam Ghandali
Maryam Ghandali
KSKadir Mert Selvi
Kadir Mert Selvi
Kelsey HuntingtonKelsey Huntington
Kelsey Huntington
AGAndrew George
Andrew George
AOAnna Ochsner
Anna Ochsner
WEWafik S. El-Deiry
Wafik S. El-Deiry
Ovarian cancer stands out as one of the most lethal gynecological cancers among women in the United States. While patients with ovarian cancer often show positive responses to treatment, it is common for the cancer to reappear and develop resistance to treatment, so it is important to explore and create novel combinations to increase patient survival rates. ATRi’s (Ataxia telangiectasia and Rad3-related inhibitors) and ONC201 monotherapies have shown efficacy in ovarian cancer in preclinical models. We hypothesized that combining ATRi’s with ONC201 would enhance this efficacy. ONC201 induces apoptosis through the TRAIL-pathway following activation of the integrated stress response and inactivation of Akt which is upregulated in ovarian cancer. Six human ovarian cancer cell lines were treated alone and with the novel drug combination of ceralasertib (ATRi) and ONC201. We found an IC50 range of 0.88-20.16 μM for ONC201 and IC50 range of 0.55-54.75 μM for ceralasertib. The combination of ONC201 plus ceralasertib resulted in PARP cleavage consistent with apoptosis along with reduction in Bcl-XL, Xiap and p-Akt expression after 72 hours of treatment. Cytokine profiling showed a decrease in markers of inflammation and tumor progression. Our data provide evidence of synergy from the combination of ATRi ceralasertib and ONC201 against Ovarian cancer cells that merits further investigation including clinical translation.